Evaluation of expressed prostatic secretion and serum using surface-enhanced Raman spectroscopy for the noninvasive detection of prostate cancer, a preliminary study

Shao, Xiaoliang; Pan, Jiahua; Wang, Yanqing; Zhu, Yao; Xu, Fan; Shangguan, Xun; Dong, Baijun; Sha, Jianjun; Chen, Na; Chen, Zhenyi; Wang, Tingyun; Liu, Shupeng; Xue, Wei

doi:10.1016/j.nano.2016.12.001

Cited by 32 publications

(18 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[20][21][22][23] Our group also reported value of SERS in early detection of PCa by analyzing components of serum and expressed prostatic secretion. 24 In this study, significantly stronger intensities at Raman spectral peaks 725, 1,328, and 1,447 cm −1 , and lower intensities at 1,014 cm −1 (P,0.01) were identified in the early biochemical recurrence group compared to bRFS group.…”

Section: Discussionsupporting

confidence: 49%

Surface-enhanced Raman spectroscopy before radical prostatectomy predicts biochemical recurrence better than CAPRA-S

Pan¹,

Shao²,

Zhu³

et al. 2019

IJN

Self Cite

View full text Add to dashboard Cite

ObjectiveThe objective of this study was to evaluate the performance of surface-enhanced Raman spectroscopy (SERS) in the prediction of early biochemical recurrence after radical prostatectomy (RP).Patients and methodsWe synthesized monodisperse gold nanoparticles as SERS-enhanced substrates and analyzed preoperative plasma samples of patients who underwent RP. The roles of clinical risk model (Cancer of the Prostate Risk Assessment [CAPRA] score) and distinctive SERS spectra on prediction of early biochemical recurrence were evaluated. The principal component analysis and linear discriminant analysis (PCA-LDA) were used to manage the spectral data and develop diagnostic algorithm.ResultsA total of 306 preoperative plasma Raman spectra from 102 patients were collected. SERS spectrum from those who developed early biochemical recurrence were compared to those who remained biochemical recurrence-free. The SERS detected more abundant circulating free nucleic acid bases in biochemical recurrence population, presenting significant stronger intensities at SERS spectral bands 725 and 1,328 cm−1. The addition of Raman spectral peak 1,328 cm−1 to CAPRA postsurgical (CAPRA-S) score significantly improved the predictive power of logistic regression model compared to simple CAPRA score (P<0.001). Meanwhile, the leave-one-out cross-validation method was used to validate the PCA-LDA model and revealed the sensitivity, specificity, and accuracy of 65.8%, 87.5%, and 79.4%, respectively. The receiver operating characteristic (ROC) curve was used to evaluate the performance of different models. Area under the ROC curve of the CAPRA-S score model alone was 0.77, however, when combined with Raman spectral peak 1,328 cm−1, it improved to 0.81.ConclusionOur primary results suggested that SERS could be a meaningful technique for prediction of early biochemical recurrence in prostate cancer.

show abstract

Section: Discussionsupporting

confidence: 49%

Surface-enhanced Raman spectroscopy before radical prostatectomy predicts biochemical recurrence better than CAPRA-S

Pan¹,

Shao²,

Zhu³

et al. 2019

IJN

Self Cite

View full text Add to dashboard Cite

show abstract

“…The band at 497 cm −1 corresponds to L‐arginine and the band at 798 is associated with the B conformation of DNA, and both are negative, therefore, related to PNT2 cells .…”

Section: Resultsmentioning

confidence: 99%

Raman spectroscopy for accurately characterizing biomolecular changes in androgen‐independent prostate cancer cells

Corsetti

Rabl

McGloin

et al. 2017

Journal of Biophotonics

View full text Add to dashboard Cite

Metastatic prostate cancer resistant to hormonal manipulation is considered the advanced stage of the disease and leads to most cancer-related mortality. With new research focusing on modulating cancer growth, it is essential to understand the biochemical changes in cells that can then be exploited for drug discovery and for improving responsiveness to treatment. Raman spectroscopy has a high chemical specificity and can be used to detect and quantify molecular changes at the cellular level. Collection of large data sets generated from biological samples can be employed to form discriminatory algorithms for detection of subtle and early changes in cancer cells. The present study describes Raman finger printing of normal and metastatic hormone-resistant prostate cancer cells including analyses with principal component analysis and linear discrimination. Amino acid-specific signals were identified, especially loss of arginine band. Androgen-resistant prostate cancer cells presented a higher content of phenylalanine, tyrosine, DNA and Amide III in comparison to PNT2 cells, which possessed greater amounts of L-arginine and had a B conformation of DNA. The analysis utilized in this study could reliably differentiate the 2 cell lines (sensitivity 95%; specificity 88%).

show abstract

“…In these studies, cancer identification was done using PCA‐LDA and validated using leave‐one‐out cross‐validation and receiver operator curve analysis. In one such study, prostatic secretion was used as liquid biopsy biomarker for SERS‐based detection of prostate cancer by comparing samples from 20 prostate cancer patients and 20 benign prostatic hyperplasia patients . Although diagnostic efficacy of this study was comparatively lower than the serum‐based study, the sensitivity, specificity, and accuracy were observed to be higher for prostatic secretion than serum samples.…”

Section: In Vitro Detection Of Biomarkers With Sers For Cancer Diagnomentioning

confidence: 83%

Advances in surface‐enhanced Raman spectroscopy for cancer diagnosis and staging

Chakraborty

Ghosh

Barui

2019

J Raman Spectroscopy

View full text Add to dashboard Cite

Surface‐enhanced Raman spectroscopy (SERS) is rapidly emerging as a bioanalytical tool for cancer diagnosis and therapy. The SERS‐based molecular diagnostics have progressed from proof‐of‐concept studies towards analysis in animal models as well as for in vitro clinical diagnostics in the last decade. Recently, SERS has also been implemented in screening, diagnosis, and staging of clinical cancer samples. Moreover, in vivo SERS imaging has been implemented for mapping the extent of tumor growth and metastasis; SERS nanoparticles have also enabled image‐guided therapies strongly indicating SERS technology can significantly complement the practice of oncology. Despite the progress, widespread clinical translation of SERS nanoparticles is still challenging. Current SERS strategies in diagnostic oncology require further development and standardization to progress from bench‐top to point‐of‐care applications. The present review critically analyzes the current state of the art about various strategies for SERS‐based cancer detection and staging from cellular metabolites, exosomes, circulating tumor cells, extracellular fluids, and cancer cells.

show abstract

Evaluation of expressed prostatic secretion and serum using surface-enhanced Raman spectroscopy for the noninvasive detection of prostate cancer, a preliminary study

Cited by 32 publications

References 26 publications

Surface-enhanced Raman spectroscopy before radical prostatectomy predicts biochemical recurrence better than CAPRA-S

Surface-enhanced Raman spectroscopy before radical prostatectomy predicts biochemical recurrence better than CAPRA-S

Raman spectroscopy for accurately characterizing biomolecular changes in androgen‐independent prostate cancer cells

Advances in surface‐enhanced Raman spectroscopy for cancer diagnosis and staging

Contact Info

Product

Resources

About